Skip to main content
. 2021 Dec 15;131(24):e140436. doi: 10.1172/JCI140436

Figure 8. Double inhibition of PI3K and WWP1 suppresses tumor growth in PDX models.

Figure 8

(A–C) Analysis of the size and weight of PDX tumors derived from ER-positive breast cancer (HCl-011). Mice were treated orally with vehicle, BYL719 (20 mg/kg), I3C (200 mg/kg), or a combination of BYL719 and I3C, 5 days a week from week 4 after implantation (n = 6 in combo arm and 7 in the other arms). Data are shown as the mean ± SEM for size and mean ± SD for weight. (D–F) Analysis of the size and weight of the PDX derived from TNBC (TM00089). Mice were treated with the indicated compounds at the same dose as that used for the ER-positive PDX, starting on week 3 after implantation (n = 10 per group). Data are shown as the mean ± SEM for size and mean ± SD for weight. *P < 0.05, **P < 0.01, and ***P < 0.005, by linear mixed-effects model (A and D) and 1-way ANOVA followed by Tukey-Kramer multiple-comparison test (B and E).